Wall Street analysts forecast that Henry Schein, Inc. (NASDAQ:HSIC) will post earnings of $0.93 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Henry Schein’s earnings, with the lowest EPS estimate coming in at $0.88 and the highest estimate coming in at $1.00. Henry Schein posted earnings per share of $1.03 during the same quarter last year, which indicates a negative year-over-year growth rate of 9.7%. The business is expected to report its next quarterly earnings report on Monday, November 1st.
On average, analysts expect that Henry Schein will report full year earnings of $4.31 per share for the current fiscal year, with EPS estimates ranging from $4.23 to $4.41. For the next financial year, analysts anticipate that the firm will post earnings of $4.58 per share, with EPS estimates ranging from $4.38 to $4.89. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Henry Schein.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 3rd. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. Henry Schein had a net margin of 5.09% and a return on equity of 15.86%. The business had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.87 billion. Henry Schein’s revenue was up 76.2% on a year-over-year basis.
NASDAQ HSIC opened at $77.72 on Thursday. The company has a 50-day simple moving average of $77.20 and a two-hundred day simple moving average of $76.15. The company has a quick ratio of 0.98, a current ratio of 1.79 and a debt-to-equity ratio of 0.18. Henry Schein has a 12-month low of $59.44 and a 12-month high of $83.45. The firm has a market cap of $10.86 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 1.32 and a beta of 0.88.
Institutional investors have recently bought and sold shares of the company. JLB & Associates Inc. increased its holdings in shares of Henry Schein by 1.6% in the 2nd quarter. JLB & Associates Inc. now owns 88,584 shares of the company’s stock worth $6,572,000 after buying an additional 1,401 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Henry Schein by 70.9% during the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 17,105 shares of the company’s stock valued at $1,269,000 after purchasing an additional 7,095 shares during the last quarter. Stephens Investment Management Group LLC grew its holdings in Henry Schein by 8.5% during the 1st quarter. Stephens Investment Management Group LLC now owns 76,827 shares of the company’s stock valued at $5,320,000 after purchasing an additional 6,011 shares during the last quarter. Lodge Hill Capital LLC bought a new position in Henry Schein during the 2nd quarter valued at about $14,096,000. Finally, Voloridge Investment Management LLC grew its holdings in Henry Schein by 21.1% during the 1st quarter. Voloridge Investment Management LLC now owns 94,449 shares of the company’s stock valued at $6,540,000 after purchasing an additional 16,473 shares during the last quarter. Hedge funds and other institutional investors own 93.16% of the company’s stock.
About Henry Schein
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Read More: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.